M&A / Deals RA Capital targets China with latest SPAC deal BioPharma DiveThe prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.M&A / DealsRead full story pharminent March 24, 2026 (Last updated: March 25, 2026) BioPharma Dive The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Immutrin raises $87M to advance drug for progressive heart diseaseNext: Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
